DeutschNewstral
Article
bizjournals.com on 2018-07-20 18:53
Main Line synthetic cannabinoid developer seeking $32.5M from stock sale
Related news
- Main Line pharma company developing synthetic cannabinoid therapies narrows its focusbizjournals.com
- Developer of synthetic cannabinoid therapies expands management teambizjournals.com
- Synthetic cannabinoid therapy developer goes public in $42M IPObizjournals.com
- South Jersey cannabinoid drug developer raises $34.1 millionbizjournals.com
- TSynthetic cannabinoid reduces sleep apneatoday.uic.edu
- GFourth synthetic cannabinoid related death reportedgreeneprairiepress.com
Local health officials issue synthetic cannabinoid warningpikepress.com- Main Line cell therapy developer raises $50Mbizjournals.com
- Chester Co. firm's synthetic cannabinoid gel starts next testing phasebizjournals.com
Bleeding from synthetic cannabinoid use causing illness, deathal.com
Federal charges for Adams man in "massive" synthetic cannabinoid operationberkshireeagle.com
Health department warns over synthetic cannabinoid death threatrockrivertimes.com- TBoard of Aldermen begins exploration of synthetic cannabinoid banthesomervilletimes.com
Synthetic Cannabinoid Spice Products Linked To Unusual Severe Bleeding CasesForbes
Synthetic Cannabinoid Key Ingredient In Bad K2 Batchnewhavenindependent.org- GSynthetic Cannabinoid Market – Global Outlook and Forecast 2022-2028galleonnews.com
Synthetic Cannabinoid Users Can Exhibit Bizarre and Violent Behaviorsbirminghamtimes.com- Federal charges for Adams man in 'massive' synthetic cannabinoid operationberkshireeagle.com
12 teens hospitalized after taking illegal synthetic cannabinoid drugtimesofisrael.com